[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581872":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":32,"locations":42,"responsibleParty":58,"collaborators":23,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":23,"enrollmentInfo":70,"targetDuration":23,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":89,"whyStopped":23,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Montreal Heart Institute","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Dietary Supplement: Vitamin K","EXPERIMENTAL","Participants receive 0.5 mg\u002Fday phylloquinone orally for 12 weeks",[9],{"label":14,"type":15,"description":16,"interventionNames":17},"Dietary Supplement: Placebo","PLACEBO_COMPARATOR","Participants receive daily placebo for 12 weeks",[14],[19,24],{"type":20,"name":21,"description":11,"armGroupLabels":22,"otherNames":23},"DIETARY_SUPPLEMENT","Vitamin K",[9],null,{"type":20,"name":25,"description":16,"armGroupLabels":26,"otherNames":23},"Placebo",[14],[28],{"name":29,"affiliation":30,"role":31},"Guylaine Ferland, PhD","Université de Montréal","PRINCIPAL_INVESTIGATOR",[33,38],{"name":29,"role":34,"phone":35,"phoneExt":36,"email":37},"CONTACT","+1 (514) 376-3330","3374","guylaine.ferland@umontreal.ca",{"name":39,"role":34,"phone":35,"phoneExt":40,"email":41},"Bouchra Ouliass, B.Sc.","4043","Bouchra.Ouliass@icm-mhi.org",[43],{"facility":5,"status":23,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Montreal","Quebec","H1T 1C8","Canada","CA",{"type":50,"coordinates":51},"Point",[52,53],-73.58781,45.50884,{"lat":53,"lon":52},[56,57],{"name":29,"role":34,"phone":35,"phoneExt":36,"email":37},{"name":29,"role":31,"phone":23,"phoneExt":23,"email":23},{"type":59,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100581872","vitamin-k-and-cognition-in-coronary-heart-disease-nutricog-100581872",false,"NCT06855953","Vitamin K and Cognition in Coronary Heart Disease (NutriCog)","Vitamin K Supplementation to Improve Cognition of Patients With Coronary Heart Disease: a Randomized Controlled Pilot Study","Nutricog","Inclusion Criteria:\n\n* Men and women\n* Age 60 years and older\n* Medically documented stable Coronary Heart Disease (CHD)\n* Daily dietary intakes of phylloquinone \\\u003C150 mcg\n* Non-consumption of vitamin K supplements (i.e. K1 or K2, singly or in combination with other nutrients), or other cognitive aids\n* Good French or English understanding\n* Physical exercise not exceeding 2.5 hours\u002Fweek of moderate to vigorous aerobic activity\n* Capacity and willingness to sign informed consent\n\nExclusion Criteria:\n\n* Recent acute coronary syndrome (\\\u003C3 months) or recent coronary revascularization (bypass surgery or percutaneous coronary intervention, \\\u003C3 months)\n* Known left ventricular dysfunction (LVEF \\\u003C 40%) or chronic heart failure\n* Recent modification of medication (\\\u003C2 weeks)\n* Warfarin (Coumadin) use\n* Cognitive impairment (based on telephone version of the Mini-Mental State Examination test, score \\\u003C19\u002F23)\n* Diagnosis of depression or uncontrolled anxiety\n* Malabsorption disorder (advanced liver disease, Crohn's disease)\n* Patient with auditory or vision impairments not properly corrected by glasses or hearing aids\n* Unable to read the informed consent form or unable to understand the oral explanations provided by the assessor","ALL","60 Years",{"count":71,"type":72},40,"ESTIMATED","INTERVENTIONAL",[75],"NA","The purpose of this pilot study is to obtain a preliminary assessment of the effect of VK supplementation on cognitive performance and vascular function in adults with stable Coronary Heart Disease (CHD)",[78],"Coronary Heart Disease",[80,81,82,83,84,85,86,87,21,88],"Coronary heart disease (CHD)","Cognition","Cerebral vasoreactivity","Nutrition","Heart disease","Cardiovascular disease","Vitamins","Micronutrients","Vitamin K1","NOT_YET_RECRUITING","2025-02-25",{"date":92,"type":93},"2025-03-04","ACTUAL",{"date":95,"type":72},"2025-03-17",{"date":97,"type":72},"2027-03",{"name":5,"class":6},1]